A Phase IIIb/IV Safety Trial of Flat Dose Nivolumab in Combination with Ipilimumab in Participants with Non-Small Cell Lung Cancer

Status: Completed

Phase of Trial: Phase III/IV

Latest Information Update: 19 Jun 2023

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

19 Nov 2022 Pooled analysis from CheckMate 227 Part 1, 817 cohort A, 568 Part 1, and 012) assessing OS, PFS, ORR, DOR, and safety published in the Annals of Oncology
29 Aug 2022 Results of pooled analysis form CheckMate 227 Part 1, CheckMate 817 cohort A, CheckMate 568 Part 1 analyzing safety of First-line Nivolumab Plus Ipilimumab in Patients With Metastatic Non-Small Cell Lung Cancer, published in the Journal of Thoracic Oncology
16 May 2022 This trial has been completed in Netherlands, according to European Clinical Trials Database record.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com